Cite
APA Citation
Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K., Azim, H., Al-Sakaff, N., Lauer, S., Shing, M., Pivot, X., & , (2017). safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European journal of cancer, 82, 237–246. http://access.bl.uk/ark:/81055/vdc_100048315377.0x000019